In a new study entitled “Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial,” researchers performed the first human trial to investigate the therapeutic potential of endothelial progenitor cells in repairing the damaged vessels in pulmonary arterial hypertension patients who have failed to…
Dublin, Ireland, based biopharmaceutical company Mallinckrodt plc reports that its INOmax (nitric oxide) vasodilator inhalation device has received regulatory approval in Australia and Japan for treating pulmonary hypertension in conjunction with heart surgery. The Australian Therapeutic Goods Administration (TGA) has approved INOmax for peri- and post-operative pulmonary hypertension…
November is Pulmonary Hypertension Awareness Month and the Pulmonary Hypertension Association (PHA) is planning to launch a new public service campaign called Heart2CurePH that promises to increase understanding of pulmonary hypertension (PH). The worldwide educational campaign will include TV, radio, and place-based and print materials, while anyone on social media can…
The latest comic book in a peer-reviewed series on pulmonary hypertension (PH) has been launched by Medikis, with the collaboration of the Imperial College Healthcare NHS Trust. The comic book, entitled Medikidz Explains Pulmonary Arterial Hypertension, aims to increase knowledge about the life-threatening disease among younger audiences.
Irving, Texas-based Reata Pharmaceuticals, Inc. announced initial data from the LARIAT (A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension) trial (ClinicalTrials.gov Identifier: NCT02036970) evaluating bardoxolone methyl in pulmonary arterial hypertension (PAH) patients at the annual meeting of the 2015…
GlaxoSmithKline (GSK) recently announced that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has released a positive recommendation for its application to expand the existing therapeutic indication for pulmonary arterial hypertension (PAH) combination treatment Volibris® (ambrisentan) — a selective endothelin type-A receptor antagonist. The therapy is currently approved…
Obesity is a prevalent comorbidity of pulmonary arterial hypertension (PAH), according to a recent study that examined the presence of metabolic syndrome in patients with PAH. In fact, a large body of research has examined obesity-related PAH. However, patients with both of…
Actelion Ltd. announced that it will give poster presentation of results from the Phase III GRIPHON clinical trial of selexipag (Uptravi®). The presentation, to be held at the American College of Chest Physicians’ CHEST Congress in Montréal, Canada, will discuss safety and efficacy results of the investigational drug in pulmonary…
Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) or recurrent CTEPH in Wales now have access to Bayer’s therapy Adempas (riociguat) — a soluble guanylate cyclase (sGC) stimulator that works by relaxing blood vessels and increasing the supply of blood to the lungs, which helps reduce the workload of the heart. The All Wales Medicines…
In a new study, researchers have investigated the impact of cancer diagnosis on the prediction of right ventricular dysfunction (RVD) in acute pulmonary embolism (PE) patients using cardiac troponin I (cTnI). The study, entitled “Impact of cancer on the effectiveness of cardiac Troponin I to predict right ventricular…
In a new study entitled “Signaling pathways underlying skeletal muscle wasting in experimental pulmonary arterial hypertension,” researchers investigated the potential mechanisms underlying patients with pulmonary arterial hypertension characteristic skeletal muscle abnormalities. The researchers identified that muscle loss is prompted by accumulation of dysfunctional mitochondrias and ineffective removal of damaged…
A recently published paper in Journal of Pathology and Translational Medicine entitled “Therapeutic Effects of Umbilical Cord Blood Derived Mesenchymal Stem Cell-Conditioned Medium on Pulmonary Arterial Hypertension in Rats” suggests that human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) may be useful…
Get regular updates to your inbox.